Grail said Monday it has agreed a private placement expected to raise roughly $325 million to fund commercial expansion and reimbursement efforts for its Galleri circulating tumor DNA (ctDNA) cancer-screening test. The deal, which includes participation from Deep Track Capital, Farallon and other institutional investors, follows recent data the company has presented showing Galleri’s incremental detection when added to standard screening. Grail said the proceeds, in combination with existing cash and a conditional $110 million Samsung investment, should fund operations into 2030. Company statements emphasize the capital will support market access work and reimbursement negotiations that have constrained adoption to date. Investors reacted immediately: Grail shares rose about 19% in morning trading after the financing was announced, reflecting renewed market confidence in the company’s commercial strategy and the broader early-cancer detection market.